Aptose Biosciences Inc (APTO) Return on Equity ROE from the first quarter 2026 to first quarter 2025 and annually, average high and low, overall ranking from Mar 31 2026 to Mar 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Aptose Biosciences Inc   (APTO)

Aptose Biosciences Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Aptose Biosciences Inc in the first quarter 2026?
Due to the lack of equity, it was not possible to calculate Aptose Biosciences Inc 's return on equity (ROE) in its first quarter 2026

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -28 -25 -19 -21 -21
Return On Equity (TTM) - - - - -
APTO's Total Ranking # # # # #
Equity (TTM) in Millions -35 -27 -19 -14 -7
Seq. Equity Change - - - - -
Seq. Net Income Change - - - - -

Back to APTO Management Effectiveness >> APTO's 5 Years Annual ROE >> Compare APTO ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





APTO Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions -27 -5 -3 38 74
Y / Y Equity Change - - - -49.16 % -37.57 %
Net Income in Millions -25 -25 -51 -42 -65
Y / Y Net Income Change - - - - -
Return On Equity - - - -110.82 % -88.04 %

Back to APTO Management Effectiveness >> APTO's 5 Years Annual ROE >> Compare APTO ROE to its Competitors




More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
APTO's' Return on Equity at Yahoo Finance
APTO's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for APTO's Competitors
Subscribers only: Roe for Aptose Biosciences Inc 's Suppliers
Subscribers only: Return On Equity for APTO's Customers




Companies with similar Return On Equity at Mar 31 2026, within Healthcare Sector ROE
Aveanna Healthcare Holdings Inc   242.29 %
Q32 Bio Inc   230.68 %
Emmis Acquisition Corp   224.85 %
Interpace Biosciences Inc   215.31 %
Coherus Oncology inc   214.57 %
Oncotelic Therapeutics Inc   183.27 %
Arbutus Biopharma Corp  169.38 %
Rigel Pharmaceuticals Inc  147.03 %
Fortress Biotech Inc   140.48 %
Halozyme Therapeutics Inc   126.27 %
Petros Pharmaceuticals inc   124.23 %
Advanced Biomed Inc.  121.71 %
Medpace Holdings Inc   120.89 %
Capforce Inc   110.42 %
Eli Lilly And Company  101.17 %
Qhslab Inc   91.63 %
Amgen Inc   89.41 %
Exelixis Inc   88.60 %
Entera Bio Ltd   87.97 %
Tg Therapeutics Inc   87.36 %
Alnylam Pharmaceuticals Inc   86.11 %
Zevra Therapeutics Inc   81.34 %
Pulmatrix Inc   78.57 %
Earth Science Tech Inc   71.44 %
Idexx Laboratories Inc  70.87 %
Elite Pharmaceuticals Inc   68.60 %
Escalon Medical Corp   66.85 %
3m Company  65.54 %
Aurinia Pharmaceuticals Inc   64.48 %
Lifemd Inc   63.70 %

Date modified: 2026-06-23T17:39:04+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.